Cellipont Bioservices and BobcatBio Announce Strategic Collaboration for Macrophage Cell Therapy

Partnership aims to advance novel cancer treatment approach into clinical trials for solid tumors and lymphomas

Mar. 17, 2026 at 3:13pm

Got story updates? Submit your updates here. ›

Cellipont Bioservices, a leading cell therapy contract manufacturer, has announced a strategic collaboration with BobcatBio, a clinical-stage biotech company pioneering a macrophage-based cellular therapy for solid tumors and lymphomas. Under the agreement, Cellipont will perform Phase I manufacturing of BobcatBio's RB-1355 therapy to support the company's ongoing clinical trials.

Why it matters

This collaboration brings together Cellipont's expertise in cell therapy development and manufacturing with BobcatBio's innovative macrophage-based approach, which holds transformative potential to redefine cancer treatment by offering an alternative to traditional, often harsh therapies like chemotherapy and radiation. If successful, this collaboration could lead to a new class of effective and more tolerable cancer treatments.

The details

BobcatBio's RB-1355 therapy leverages the versatility and power of a patient's own macrophages to elicit a robust, targeted immune response against solid tumors and lymphomas. Early clinical findings indicate the therapy is well-tolerated and can be effectively administered without the need for lymphodepleting chemotherapy. Cellipont will now manufacture the RB-1355 product to support BobcatBio's ongoing clinical trials.

  • The strategic collaboration was announced on March 17, 2026.

The players

Cellipont Bioservices

A leading cell therapy Contract Development and Manufacturing Organization (CDMO) that specializes in advancing cell therapies.

BobcatBio

A clinical-stage biotechnology company that is pioneering the development of RB-1355, a first-of-its-kind cellular therapy that leverages macrophages to treat solid tumors and lymphomas.

Darren Head

CEO of Cellipont Bioservices.

Stephen Rocamboli

CEO of BobcatBio.

Got photos? Submit your photos here. ›

What they’re saying

“At Cellipont, we are committed to supporting innovators who are pushing the boundaries of what cell therapy can do for patients. BobcatBio's work reflects the kind of bold science this field needs, and we are proud to support the advancement of a program with the potential to open new possibilities in solid tumors. Collaborations like this are about more than manufacturing. They are about helping bring promising therapies closer to patients and families who are waiting for better options.”

— Darren Head, CEO, Cellipont Bioservices

“BobcatBio is advancing a highly differentiated approach to cell therapy, and we are pleased to partner with Cellipont as we continue to move this program forward. As we work to bring our macrophage-based therapy closer to patients, it is critical to have a manufacturing partner that understands both the complexity of cell therapy development and the urgency of delivering new treatment options. Cellipont brings the technical expertise, quality focus, operational rigor, and scalable infrastructure needed to advance BobcatBio's innovative cellular therapy.”

— Stephen Rocamboli, CEO, BobcatBio

What’s next

Cellipont Bioservices will perform Phase I cell product manufacturing of BobcatBio's RB-1355 therapy to support the company's ongoing solid tumor and lymphoma clinical trials.

The takeaway

This strategic collaboration between Cellipont Bioservices and BobcatBio brings together expertise in cell therapy manufacturing and development of a novel macrophage-based approach to cancer treatment. If successful, this partnership could lead to a transformative new class of cancer therapies that offer improved patient outcomes and quality of life compared to traditional treatments.